Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?

Core Insights - CRISPR Therapeutics has achieved significant milestones, including the approval of Casgevy, the first gene-editing therapy using the CRISPR system for rare blood diseases [1] - Despite past achievements, the company has underperformed in the market, but upcoming catalysts in its pipeline have generated investor interest [2] - The company's gene-editing approach has the potential to transform treatment standards in areas with high unmet medical needs, with several promising medicines expected to show progress in the next 12 to 18 months [3] Pipeline Developments - Zugo-cel is a potential treatment for various cancers and autoimmune diseases, designed to overcome limitations of traditional CAR-T therapies by using healthy donor cells instead of patients' own cells [4][5] - Zugo-cel has received the Regenerative Medicine Advanced Therapy designation from the FDA, which aims to expedite the development of treatments with promising early clinical evidence [6] - Other pipeline candidates include CTX310, aimed at lowering bad cholesterol, and SRSD107, a next-generation anticoagulant [6]